Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 2
  • Print publication year: 2010
  • Online publication date: February 2010

Section 3A - Description of muscle disease – general aspects

References

1. G. Karpati, M. Sinnreich, The molecular era of myology. J. Neuropathol. Exp. Neurol. 62:12 (2003), 1203–1210.
2. R. Lane, G. Fuller, Clinical presentation: symptoms and signs of muscle disease and their interpretation. In Handbook of Muscle Disease, First Edition, ed. R. Lane. (New York: Marcel Dekker, 1996), pp. 1–17.
3. R. J. Barohn, General approach to muscle diseases. In Cecil Textbook of Medicine, eds. L. Golman, D. Ausiello. (Philadelphia, PA: W. B. Saunders, 2004), pp. 2370–2379.
4. A. A. Amato, G. S. Gronseth, C. E. Jackson, et al., Inclusion body myositis: clinical and pathological boundaries. Ann. Neurol. 40:4 (1996), 581–586.
5. E. A. Sekul, C. Chow, M. C. Dalakas, Magnetic resonance imaging of the forearm as a diagnostic aid in patients with sporadic inclusion body myositis. Neurology 48:4 (1997), 863–866.
6. R. K. H. Petty, A. E. Harding, J. A. Morgan-Hughes, The clinical features of mitochondrial myopathy. Brain 109 (1986), 915–938.
7. J. S. Katz, G. I. Wolfe, D. K. Burns, W. W. Bryan, J. L. Fleckenstein, R. J. Barohn, Isolated neck extensor myopathy: a common cause of dropped head syndrome. Neurology 46:4 (1996), 917–921.
8. I. Mahjneh, G. Marconi, A. Paetau, A. Saarinen, T. Salmi, H. Somer, Axial myopathy – an unrecognised entity. J. Neurol. 249:6 (2002), 730–734.
9. N. Shahrizaila, W. J. Kinnear, A. J. Wills, Respiratory involvement in inherited primary muscle conditions. J. Neurol. Neurosurg. Psychiatry 77:10 (2006), 1108–1115.
10. T. Shahrizaila, W. Kinnear, Recommendations for respiratory care of adults with muscle disorders. Neuromuscul. Disord. 17:1 (2007), 13–15.
11. K. R. Mills, R. H. T. Edwards, Investigative strategies for muscle pain. J. Neurol. Sci. 58 (1983), 73–88.
12. M. Filosto, P. Tonin, G. Vattemi, et al., The role of muscle biopsy in investigating isolated muscle pain. Neurology 68:3 (2007), 181–186.
13. J. T. Kissel, Muscle biopsy in patients with myalgia: still a painful decision. Neurology 68:3 (2007), 170–171.
14. J. T. Kissel, The problem of fibromyalgia. Muscle Nerve 25:4 (2002), 473–476.
15. D. Hilton-Jones, The clinical features of some miscellaneous neuromuscular disorders. In Disorders of Voluntary Muscle, Sixth Edition, eds. J. Walton, G. Karpati, D. Hilton-Jones. (Edinburgh: Churchill Livingstone, 1994), pp. 967–987.
16. J. Kissel, R. G. Miller, Muscle pain and fatigue. In Muscle Diseases, eds. A. H. Schapira, R. C. Griggs. (Woburn: Butterwort-Heinemann, 1999), pp. 33–58.
17. Z. Argov, F. L. Mastaglia, Drug-induced neuromuscular disorders in man. In Disorders of Voluntary Muscle, Sixth Edition, eds. J. Walton, G. Karpati, D. Hilton-Jones. (Edinburgh: Churchill Livingstone, 1994), pp. 989–1029.
18. S. Franc, S. Dejager, E. Bruckert, M. Chauvenet, P. Giral, G. Turpin, A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc. Drugs Ther. 17:5–6 (2003), 459–465.
19. S. K. Baker, Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve 31(5) (2005), 572–580.
20. W. W. Campbell, Statin myopathy: the iceberg or its tip?Muscle Nerve 34:4 (2006), 387–390.
21. R. Layzer, Muscle pain, cramps and fatigue. In Myology, Second Edition, eds. A. Engel, C. Franzini-Armstrong. (New York: McGraw-Hill, 1994), pp. 1754–1768.
22. R. G. Auger, AAEM minimonograph #44: diseases associated with excess motor unit activity. Muscle Nerve 17:11 (1994), 1250–1263.
23. T. M. Miller, R. B. Layzer, Muscle cramps. Muscle Nerve 32:4 (2005), 431–442.
24. P. S. Harper, Myotonic Dystrophy, Third Edition. (London: W. B. Saunders, 2001.)
25. J. W. Day, K. Ricker, J. F. Jacobsen, et al., Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 60:4 (2003), 657–664.
26. A. J. Hudson, G. C. Ebers, D. E. Bulman, The skeletal muscle sodium and chloride channel diseases. Brain 118: (1995), 547–563.
27. E. Fournier, K. Viala, H. Gervais, et al., Cold extends electromyography distinction between ion channel mutations causing myotonia. Ann. Neurol. 60:3 (2006), 356–365.
28. J. A. P. Hiel, P. J. H. Jongen, P. J. E. Poels, et al., Sarcoplasmic reticulum Ca2+-adenosine triphosphate deficiency (Brody's disease). In Handbook of Muscle Disease, ed. R. J. M. Lane. (New York: Marcel Dekker, 1996), pp. 473–478.
29. S. A. Greenberg, Acquired rippling muscle disease with myasthenia gravis. Muscle Nerve 29:1 (2004), 143–146.
30. R. C. Betz, B. G. Schoser, D. Kasper, et al., Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease. Nat. Genet. 28:3 (2001), 218–219.
31. K. Ricker, R. T. Moxley, R. Rohkamm, Rippling muscle disease. Arch. Neurol. 46 (1989), 405–408.
32. P. Shillito, P. C. Molenaar, A. Vincent, et al., Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann. Neurol. 38:5 (1995), 714–722.
33. I. K. Hart, J. Newsom-Davis, Neuromyotonia. In Handbook of Muscle Disease, ed. R. J. M. Lane. (New York: Marcel Dekker, 1996), pp. 355–363.
34. J. Newsom-Davis, The emerging diversity of neuromuscular junction disorders. Acta Myol. 26:1 (2007), 5–10.
35. J. T. Kissel, R. J. Elble, Stiff-person syndrome: stiff opposition to a simple explanation. Neurology 51:1 (1998), 11–14.
36. M. C. Dalakas, Advances in the pathogenesis and treatment of patients with stiff person syndrome. Curr. Neurol. Neurosci. Rep. 8:1 (2008), 48–55.
37. L. B. Krupp, D. A. Pollina, Mechanisms and management of fatigue in progressive neurological disorders. Curr. Opin. Neurol. 9:6 (1996), 456–460.
38. J. Sieb, A. Penn, Myoglobinuria. In Myology, Third Edition, eds. A. Engel, C. Franzini-Armstrong. (New York: McGraw-Hill, 2004), pp. 1677–1692.
39. C. Y. Tsao, J. R. Mendell, J. Rusin, M. Luquette, Congenital muscular dystrophy with complete laminin-alpha2-deficiency, cortical dysplasia, and cerebral white-matter changes in children. J. Child Neurol. 13:6 (1998), 253–256.
40. C. Y. Tsao, J. R. Mendell, The childhood muscular dystrophies: making order out of chaos. Semin. Neurol. 19:1 (1999), 9–23.
41. C. Godfrey, E. Clement, R. Mein, et al., Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain 130:Pt 10 (2007), 2725–2735.
42. M. A. Mullie, A. E. Harding, R. K. Petty, H. Ikeda, J. A. Morgan-Hughes, M. D. Sanders, The retinal manifestations of mitochondrial myopathy. A study of 22 cases. Arch Ophthalmol. 103:12 (1985), 1825–1830.
43. J. Kissel, J. R. Mendell, Endocrine myopathies. In Handbook of Clinical Neurology, eds. L. P. Rowland, S. DiMauro. (New York: Elsevier Science, 1992), pp. 527–551.
44. M. Hirano, G. Silvestri, D. M. Blake, et al., Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder. Neurology 44:4 (1994), 721–727.
45. M. C. Lara, M. L. Valentino, J. Torres-Torronteras, M. Hirano, R. Marti, Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): biochemical features and therapeutic approaches. Biosci. Rep. 27:1–3 (2007), 151–163.
46. J. Hayes, F. Veyckemans, B. Bissonnette, Duchenne muscular dystrophy: an old anesthesia problem revisited. Paediatr. Anaesth. 18:2 (2008), 100–106.
47. G. A. Suarez, J. J. Kelly, The dropped head syndrome. Neurology 42 (1992), 1625–1627.
48. Aids to the Examination of the Peripheral Nervous System, Fourth Edition. (Oxford: Saunders, 2000.)
49. R. Tawil, M. P. McDermott, J. R. Mendell, J. Kissel, R. C. Griggs, Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing. FSH-DY Group. Neurology 44:3 Pt 1 (1994), 442–446.
50. T. Munsat, Quantification of Neurologic Deficit. (Stoneham: Butterworth, 1989.)
51. K. E. Personius, S. Pandya, W. M. King, R. Tawil, M. P. McDermott, Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group. Phys. Ther. 74:3 (1994), 253–263.
52. M. Brooke, A Clinician's View of Neuromuscular Diseases. (Baltimore, MD: Williams and Wilkins, 1986.)
53. R. A. C. Hughes, D. Bihari, Acute neuromuscular respiratory paralysis. J. Neurol. Neurosurg. Psychiatry 56 (1993), 334–343.
54. V. Dubowitz, Muscle Disorders in Childhood, Second Edition. (London: Saunders, 1995.)
55. F. M. S. Tome, D. Chateau, A. Helbling-Leclerc, M. Fardeau, Morphological changes in muscle fibers in oculopharyngeal muscular dystrophy. Neuromuscul. Disord. 7:Suppl 1 (1997), S63–S69.
56. N. Chahin, A. G. Engel, Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70:6 (2008), 418–424.
57. J. T. Kissel, Polymyositis: not a unicorn or mythological beast. . .but maybe a duck?Neurology 70:6 (2008), 414–415.
58. D. Hilton-Jones, M. Squier, D. J. TaylorP. Matthews, Metabolic Myopathies, First Edition. (London: W. B. Saunders, 1995.)
59. R. G. Haller, L. A. Bertocci, Exercise evaluation of metabolic myopathies. In Myology, Second Edition, eds. A. G. Engel, C. Franzini-Armstrong. (New York: McGraw-Hill, 1994), pp. 807–821.
60. R. Lane, Exercise tests. In Handbook of Muscle Disease, ed. R. Lane. (New York: Marcel Dekker, 1996.)
61. S. L. Venance, S. C. Cannon, D. Fialho, et al., The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain 129:Pt 1 (2006), 8–17.
62. E. T. Wong, C. Cobb, M. K. Umehara, et al., Heterogeneity of serum creatine kinase activity among racial and gender groups of the population. Am. J. Clin. Pathol. 79:5 (1983), 582–586.
63. E. I. Lev, I. Tur-Kaspa, I. Ashkenazy, et al., Distribution of serum creatine kinase activity in young healthy persons. Clin. Chim. Acta 279:1–2 (1999), 107–115.
64. L. M. Brewster, G. Mairuhu, A. Sturk, G. A. van Montfrans, Distribution of creatine kinase in the general population: implications for statin therapy. Am. Heart J. 154:4 (2007), 655–661.
65. E. D'Adda, M. Sciacco, M. E. Fruguglietti, et al., Follow-up of a large population of asymptomatic/oligosymptomatic hyperCKemic subjects. J. Neurol. 253:11 (2006), 1399–1403.
66. K. G. Sim, J. Hammond, B. Wilcken, Strategies for the diagnosis of mitochondrial fatty acid beta-oxidation disorders. Clin. Chim. Acta 323:1–2 (2002), 37–58.
67. P. Kazemi-Esfarjani, E. Skomorowska, T. D. Jensen, R. G. Haller, J. Vissing, A nonischemic forearm exercise test for McArdle disease. Ann. Neurol. 52:2 (2002), 153–159.
68. R. A. Coleman, J. M. Stajich, V. W. Pact, M. A. Pericak-Vance, The ischemic exercise test in normal adults and in patients with weakness and cramps. Muscle Nerve 9 (1986), 216–221.
69. S. P. Sinkeler, R. A. Wevers, E. M. Joosten, et al., Improvement of screening in exertional myalgia with a standardized ischemic forearm test. Muscle Nerve 9 (1986), 731–737.
70. T. D. Jensen, P. Kazemi-Esfarjani, E. Skomorowska, J. Vissing, A forearm exercise screening test for mitochondrial myopathy. Neurology 58:10 (2002), 1533–1538.
71. L. Nashef, R. J. M. Lane, Screening for mitochondrial cytopathies: the sub-anaerobic threshold exercise test (SATET). J. Neurol. Neurosurg. Psychiatry 52: (1989), 1090–1094.
72. P. Laforet, C. Wary, S. Duteil, et al., [Exploration of exercise intolerance by 31P NMR spectroscopy of calf muscles coupled with MRI and ergometry.]Rev. Neurol. (Paris) 159:1 (2003), 56–67.
73. V. Dubowitz, C. Sewry, Muscle Biopsy. A Practical Approach. (China: Saunders, 2007.)
74. S. Carpenter, G. Karpati, Pathology of Skeletal Muscle. (Oxford: Oxford University Press, 2001.)
75. M. Brooke, The classification of muscle diseases. In Disorders of Voluntary Muscle, eds. G. Karpati, D. Hilton-Jones, R. C. Griggs. (Cambridge: Cambridge University Press, 2001), pp. 374–384.
76. T. M. Geel, P. M. McLaughlin, L. F. de Leij, M. H. Ruiters, K. E. Niezen-Koning, Pompe disease: current state of treatment modalities and animal models. Mol. Genet. Metab. 92:4 (2007), 299–307.

References

1. P. Sicinski, Y. Geng, A. S. Ryder-Cook, E. A. Barnard, M. G. Darlison, P. J. Barnard, The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 30 (1989), 1578–1580.
2. B. A. Valentine, B. J. Cooper, A. De Lahunta, R. O. Quinn, J. T. Blue, Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies. J. Neurol. Sci. 88 (1988), 69–81.
3. J. S. Chamberlain, Gene therapy of muscular dystrophy. Hum. Mol. Genet. 11 (2002), 2355–2362.
4. K. J. Nowak, K. E.Davies, Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep. 5 (2004), 872–876.
5. J. V. Chakkalakal, J. Thompson, R. J. Parks, B. J. Jasmin, Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies. FASEB J. 19 (2005), 880–891.
6. K. Foster, H. Foster, J. G. Dickson, Gene therapy progress and prospects: Duchenne muscular dystrophy. Gene Ther. 13 (2006), 1677–1685.
7. S. E. Haecker, H. H. Stedman, R. J. Balice-Gordon, et al., In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum. Gene Ther. 7 (1996), 1907–1914.
8. C. DelloRusso, J. M. Scott, D. Hartigan-O'Connor, et al., Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 12979–12984.
9. R. Gilbert, R. W. Dudley, A. B. Liu, B. J. Petrof, J. Nalbantoglu, G. Karpati, Prolonged dystrophin expression and functional correction of mdx mouse muscle following gene transfer with a helper-dependent (gutted) adenovirus-encoding murine dystrophin. Hum. Mol. Genet. 12 (2003), 1287–1299.
10. N. Vincent, T. Ragot, H. Gilgenkrantz, et al., Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene. Nat. Genet. 5 (1993), 130–134.
11. N. Deconinck, T. Ragot, G. Marechal, M. Perricaudet, J. M. Gillis, Functional protection of dystrophic mouse (mdx) muscles after adenovirus-mediated transfer of a dystrophin minigene. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 3570–3574.
12. G. Acsadi, H. Lochmuller, A. Jani, et al., Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. Hum. Gene Ther. 7 (1996), 129–140.
13. B. Wang, J. Li, X. Xiao, Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 13714–13719.
14. S. Q. Harper, M. A. Hauser, C. DelloRusso, et al., Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8 (2002), 253–261.
15. P. Gregorevic, M. J. Blankinship, J. M. Allen, et al., Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med. 10 (2004), 828–834.
16. N. Larochelle, W. Oualikene, P. Dunant, et al., The short MCK1350 promoter/enhancer allows for sufficient dystrophin expression in skeletal muscles of mdx mice. Biochem. Biophys. Res. Commun. 292 (2002), 626–631.
17. M. A. Hauser, A. Robinson, D. Hartigan-O'Connor, et al., Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors. Mol. Ther. 2 (2000), 16–25.
18. M. Z. Salva, C. L. Himeda, P. W. Tai, et al., Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol. Ther. 15 (2007), 320–329.
19. Q. L. Lu, G. Bou-Gharios, T. A. Partridge, Non-viral gene delivery in skeletal muscle: a protein factory. Gene Ther. 10 (2003), 131–142.
20. M. J. Molnar, R. Gilbert, Y. Lu, et al., Factors influencing the efficacy, longevity, and safety of electroporation-assisted plasmid-based gene transfer into mouse muscles. Mol. Ther. 10 (2004), 447–455.
21. G. Danialou, A. S. Comtois, R. W. Dudley, et al., Ultrasound increases plasmid-mediated gene transfer to dystrophic muscles without collateral damage. Mol. Ther. 6 (2002), 687–693.
22. H. Herweijer, J. A. Wolff, Progress and prospects: naked DNA gene transfer and therapy. Gene Ther. 10 (2003), 453–458.
23. G. Zhang, V. Budker, P. Williams, V. Subbotin, J. A. Wolff, Efficient expression of naked DNA delivered intraarterially to limb muscles of nonhuman primates. Hum. Gene Ther. 12 (2001), 427–438.
24. S. Kochanek, High-capacity adenoviral vectors for gene transfer and somatic gene therapy. Hum. Gene Ther. 10 (1999), 2451–2459.
25. R. Alba, A. Bosch, M. Chillon, Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther. 12:Suppl 1 (2005), S18–S27.
26. T. Athanasopoulos, I. R. Graham, H. Foster, G. Dickson, Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD). Gene Ther. 11:Suppl 1 (2004), S109–S121.
27. M. J. Blankinship, P. Gregorevic, J. S. Chamberlain, Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors. Mol. Ther. 13 (2006), 241–249.
28. B. C. Schnepp, K. R. Clark, D. L. Klemanski, C. A. Pacak, P. R. Johnson, Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J. Virol. 77 (2003), 3495–3504.
29. P. Gregorevic, J. M. Allen, E. Minami, et al., rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat. Med. 12 (2006), 787–789.
30. T. A. Rando, M. H. Disatnik, L. Z. Zhou, Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotides. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 5363–5368.
31. G. McClorey, S. Fletcher, S. Wilton, Splicing intervention for Duchenne muscular dystrophy. Curr. Opin. Pharmacol. 5 (2005), 529–534.
32. A. Artsma-Rus, G. J. van Ommen, Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 13 (2007), 1609–1624.
33. J. C. van Deutekom, A. A. Janson, I. B. Ginjaar, et al., Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med. 357 (2007), 2677–2686.
34. Q. L. Lu, C. J. Mann, F. Lou, et al., Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat. Med. 9 (2003), 1009–1014.
35. C. J. Mann, K. Honeyman, A. J. Cheng, et al., Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 42–47.
36. M. A. Denti, A. Rosa, G. D'Antona, et al., Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 3758–3763.
37. A. Goyenvalle, A. Vulin, F. Fougerousse, et al., Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306 (2004), 1796–1799.
38. C. Bertoni, Clinical approaches in the treatment of Duchenne muscular dystrophy (DMD) using oligonucleotides. Front. Biosci. 13 (2008), 517–527.
39. E. R. Barton-Davis, L. Cordier, D. I. Shoturma, S. E. Leland, H. L. Sweeney, Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J. Clin. Invest. 104 (1999), 375–381.
40. P. Dunant, M. C. Walter, G. Karpati, H. Lochmuller, Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle. Muscle Nerve 27 (2003), 624–627.
41. E. M. Welch, E. R. Barton, J. Zhuo, et al., PTC124 targets genetic disorders caused by nonsense mutations. Nature 447 (2007), 87–91.
42. G. Karpati, Mitigation of deleterious effects of certain abnormal genes in immature skeletal muscle cells. Trends Neurosci. 7 (1985), 524–525.
43. J. Howell, K. R. Walker, L. Davies, et al., Adenovirus and adeno-associated virus-mediated delivery of human myophosphorylase cDNA and LacZ cDNA to muscle in the ovine model of McArdle's disease: expression and re-expression of glycogen phosphorylase. Neuromuscul. Disord. 18 (2008), 248–268.
44. G. Karpati, Utrophin muscles in on the action. Nat. Med. 3 (1997), 22–23.
45. J. A. Rafael, J. M. Tinsley, A. C. Potter, A. E. Deconinck, K. E. Davies, Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. Nat. Genet. 19 (1998), 79–82.
46. J. Tinsley, N. Deconinck, R. Fisher, et al., Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat. Med. 4 (1998), 1441–1444.
47. J. M. Tinsley, A. C. Potter, S. R. Phelps, R. Fisher, J. I. Trickett, K. E. Davies, Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 384 (1996), 349–353.
48. J. R. Deol, G. Danialou, N. Larochelle, et al., Successful compensation for dystrophin deficiency by a Helper-dependent adenovirus expressing full-length utrophin. Mol. Ther. 15 (2007), 1767–1774.
49. M. Cerletti, T. Negri, F. Cozzi, et al., Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer. Gene Ther. 10 (2003), 750–757.
50. P. M. Wakefield, J. M. Tinsley, M. J. Wood, R. Gilbert, G. Karpati, K. E. Davies, Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene. Gene Ther. 7 (2000), 201–204.
51. R. Gilbert, J. Nalbantoglu, B. J. Petrof, et al., Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles. Hum. Gene Ther. 10 (1999), 1299–1310.
52. E. Mattei, N. Corbi, M. G. Di Certo, et al., Utrophin up-regulation by an artificial transcription factor in transgenic mice. PLoS ONE 2 (2007), e774.
53. I. Waheed, R. Gilbert, J. Nalbantoglu, G. H. Guibinga, B. J. Petrof, G. Karpati, Factors associated with induced chronic inflammation in mdx skeletal muscle cause posttranslational stabilization and augmentation of extrasynaptic sarcolemmal utrophin. Hum. Gene Ther. 16 (2005), 489–501.
54. I. Courdier-Fruh, A. Briguet, Utrophin is a calpain substrate in muscle cells. Muscle Nerve 33 (2006), 753–759.
55. G. Karpati, M. Molnar, Muscle fiber regeneration in human skeletal muscle diseases. In Skeletal Muscle Regeneration and Repair, eds. S. Schiaffino, T. Partridge. (New York: Springer, 2008), pp. 199–215.
56. T. Nastasi, N. Rosenthal, Boosting muscle regeneration. In Skeletal Muscle Regeneration and Repair, eds. S. Schiaffino, T. Partridge. (New York: Springer, 2008), pp. 335–355.
57. A. Dellavalle, M. Sampaolesi, R. Tonlorenzi, et al., Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat. Cell Biol. 9 (2007), 255–267.
58. M. Sampaolesi, S. Blot, G. D'Antona, et al., Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444 (2006), 574–579.
59. B. Peault, M. Rudnicki, Y. Torrente, et al., Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol. Ther. 15 (2007), 867–877.
60. A. Nadeau, G. Karpati, Are big muscles necessarily good muscles? Ann. Neurol. 63 (2008), 543–545.
61. K. R. Wagner, A. C. McPherron, N. Winik, S. J. Lee, Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann. Neurol. 52 (2002), 832–836.
62. S. Bogdanovich, K. J. Perkins, T. O. Krag, L. A. Whittemore, T. S. Khurana, Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J. 19 (2005), 543–549.
63. S. Bogdanovich, T. O. Krag, E. R. Barton, et al., Functional improvement of dystrophic muscle by myostatin blockade. Nature 420 (2002), 418–421.
64. G. Karpati, S. Carpenter, S.Prescott, Small-caliber skeletal muscle fibers do not suffer necrosis in mdx mouse dystrophy. Muscle Nerve 11 (1988), 795–803.
65. L. Passerini, P. Bernasconi, F. Baggi, et al., Fibrogenic cytokines and extent of fibrosis in muscle of dogs with x-linked golden retriever muscular dystrophy. Neuromuscul. Disord. 12 (2002), 828–835.
65. F. Andreetta, P. Bernasconi, F. Baggi, et al., Immunomodulation of TGF-beta1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: Implications for antifibrotic therapy. J. Neuroimmunol. 175 (2006), 77–86.
66. L. P. Ranum, J. W.Day, Myotonic dystrophy: RNA pathogenesis comes into focus. Am. J. Hum. Genet. 74 (2004), 793–804.
67. L. P. Ranum, T. A.Cooper, RNA-mediated neuromuscular disorders. Annu. Rev. Neurosci. 29 (2006), 259–277.
68. R. J. Osborne, C. A. Thornton, RNA-dominant diseases. Hum. Mol. Genet. 15: Spec No 2 (2006), R162–R169.
69. H. Jiang, A. Mankodi, M. S. Swanson, R. T. Moxley, C. A. Thornton, Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum. Mol. Genet. 13 (2004), 3079–3088.
70. R. N. Kanadia, K. A. Johnstone, A. Mankodi, et al., A muscleblind knockout model for myotonic dystrophy. Science 302 (2003), 1978–1980.
71. R. N. Kanadia, J. Shin, Y. Yuan, et al., Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 11748–11753.
72. E. M. Ovan-Wright, B. L. Davidson, RNAi: a potential therapy for the dominantly inherited nucleotide repeat diseases. Gene Ther. 13 (2006), 525–531.
73. J. Shao, M. I.Diamond, Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum. Mol. Genet. 16: Spec No 2 (2007), R115–R123.
74. D. J. Wells, Treatments for muscular dystrophy: increased treatment options for Duchenne and related muscular dystrophies. Gene Ther. 15:5 (2008), 1077–1078.